eMed operates an employer-focused population health platform built around an empathic agentic AI system and clinically managed GLP-1 programs. The company says its GLP-1 program achieves more than 90% member adherence—over double the industry norm—and reports an average weight loss of 21 pounds, with 99% of participants improving at least one key biomarker within six months. eMed highlights strong demand for workplace GLP-1 benefits, noting only one in five companies currently provide them. The company plans to use the new capital to further develop its AI platform and to support a capitated model designed to help employers reduce healthcare costs. eMed is led by CEO Linda Yaccarino and lists Tom Brady as its Founding Chief Wellness Officer and investor.

Total raised

$200M

Funding rounds

2

Latest round

Series A

Latest activity

Mar 2026